Status:
TERMINATED
Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
Detailed Description
The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No s...
Eligibility Criteria
Inclusion
- Obese adults with a body mass index \> or = 30 kg/m ; \> or = 27 kg/m2 for those with obesity-related comorbidities including hypertension and dyslipidemia
Exclusion
- Pregnancy
- Diabetes
- Adults with serious or unstable current or past medical conditions
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
1253 Patients enrolled
Trial Details
Trial ID
NCT00396448
Start Date
February 1 2007
End Date
February 1 2009
Last Update
November 7 2012
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Peoria, Arizona, United States, 85381
2
Pfizer Investigational Site
Newport Beach, California, United States, 92660-2452
3
Pfizer Investigational Site
Miami, Florida, United States, 33143
4
Pfizer Investigational Site
Springfield, Illinois, United States, 62704